Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.Clinical Cancer Research.  27:5536-5545. 2021
2021 Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort studyGynecologic Oncology.  163:85-92. 2021
2021 An enhanced recovery protocol decreases complication rates in high-risk gynecologic oncology patients undergoing non-emergent laparotomyInternational Journal of Gynecological Cancer.  31:647-655. 2021
2021 Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 2021
2021 Ovarian cancer, version 2.2020 2021
2021 Fluorescence Imaging of the Ureter in Minimally Invasive Pelvic Surgery 2021
2020 A Multi-atlas Approach for Active Bone Marrow Sparing Radiation Therapy: Implementation in the NRG-GY006 Trial 2020
2020 Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithmGynecologic Oncology.  159:773-777. 2020
2020 Advances in immunotherapy for cervical cancerCurrent Opinion in Oncology.  32:481-487. 2020
2020 Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group studyGynecologic Oncology.  158:562-569. 2020
2020 Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer.Clinical Practice and Cases in Emergency Medicine.  4:227-229. 2020
2020 Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): A randomized phase III trialJournal of Clinical Oncology.  38:1164-1174. 2020
2020 Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized TherapyDrugs.  80:217-227. 2020
2019 Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancerNew England Journal of Medicine.  381:2403-2415. 2019
2019 Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendationGynecologic Oncology.  155:365-373. 2019
2019 Neutrophilia and mortality in women with uterine carcinosarcomaInternational Journal of Gynecological Cancer.  29:1258-1263. 2019
2019 Assessing recurrence risk following intraperitoneal chemotherapy for ovarian cancer: A day late and a dollar short?Gynecologic Oncology Reports.  29:111-112. 2019
2019 Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment ClinicGynecologic Oncology.  154:379-382. 2019
2019 Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomitingGynecologic Oncology Reports.  29:123-125. 2019
2019 Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institutionGynecologic Oncology.  153:242-247. 2019
2019 Options for assisted reproduction in young women with uterine cancer a cost-effectiveness analysis 2019
2019 Response to “surgical management of cervical cancer by laparoscopy or laparotomy”Gynecologic Oncology Reports.  27:6-7. 2019
2019 Ovarian cancer, version 1.2019 featured updates to the nccn guidelines 2019
2019 The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reductionGynecologic Oncology.  152:127-132. 2019
2018 Enhanced Recovery After Surgery in Surgical Specialties: Gynecologic OncologySurgical Clinics of North America.  98:1275-1285. 2018
2018 Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomyGynecologic Oncology.  151:282-286. 2018
2018 The impact of racial, geographic, and socioeconomic risk factors on the development of advanced-stage cervical cancerJournal of Lower Genital Tract Disease.  22:269-273. 2018
2018 Predictors of Unplanned Reoperation for Ovarian Cancer Patients from the National Surgical Quality Improvement Program DatabaseInternational Journal of Gynecological Cancer.  28:1427-1431. 2018
2018 Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty yearsGynecologic Oncology.  150:391-397. 2018
2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer 2018
2018 High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women with Low-Grade Cervical CytologyJournal of Lower Genital Tract Disease.  22:207-211. 2018
2018 Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment ClinicGynecologic Oncology.  149:337-340. 2018
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma 2018
2018 Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?Gynecologic Oncology.  149:49-52. 2018
2018 Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcomaCancer Medicine.  7:616-625. 2018
2018 Feasibility of complete salpingectomy compared with standard postpartum tubal ligation at cesarean delivery a randomized controlled trialObstetrics and Gynecology.  132:20-27. 2018
2017 Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) studyGynecologic Oncology.  147:98-103. 2017
2017 The evolution of and evidence for opportunistic salpingectomyObstetrics and Gynecology.  130:814-824. 2017
2017 Malignant Brenner tumor associated with a germline BRCA2 mutationGynecologic Oncology Reports.  21:17-19. 2017
2017 A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group studyGynecologic Oncology.  145:291-297. 2017
2017 Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohortGynecologic Oncology.  144:274-278. 2017
2017 Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?Gynecologic Oncology.  144:125-129. 2017
2017 Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients?International Journal of Gynecological Cancer.  27:714-719. 2017
2016 Drawing the Line in Risk-Reducing Gynecologic Surgery in Women with a BRCA MutationJAMA Oncology.  2:1409-1411. 2016
2016 Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinomaGynecologic Oncology.  142:25-29. 2016
2016 See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology?Journal of Lower Genital Tract Disease.  20:243-246. 2016
2016 Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?Gynecologic Oncology.  143:617-621. 2016
2016 Staging Lymphadenectomy in Patients with Clear Cell Carcinoma of the OvaryInternational Journal of Gynecological Cancer.  26:120-124. 2016
2015 The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions.Current Obstetrics and Gynecology Reports.  4:234-239. 2015
2015 PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysisGynecologic Oncology.  139:59-62. 2015
2015 Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement projectInternational Journal of Gynecological Cancer.  25:798-801. 2015
2015 Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?Gynecologic Oncology.  136:43-47. 2015
2015 Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian cancers: An observational study ancillary analysisGynecologic Oncology.  138:267-271. 2015
2015 Laparoscopic staging of ovarian immature teratomas: A report on three cases 2015
2014 Diabetes mellitus and ovarian cancer: More complex than just increasing riskGynecologic Oncology.  135:273-277. 2014
2014 A chemoresponse assay for prediction of platinum resistance in primary ovarian cancerAmerican Journal of Obstetrics and Gynecology.  211:68.e1-68.e8. 2014
2014 Black race independently predicts worse survival in uterine carcinosarcomaGynecologic Oncology.  133:238-241. 2014
2014 Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. 2014
2014 Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancerInternational Journal of Gynecological Cancer.  24:1480-1485. 2014
2014 Primary invasive breast carcinoma arising in mammary-like glands of the vulva managed with excision and sentinel lymph node biopsyGynecologic Oncology Case Reports.  7:7-9. 2014
2014 Radical surgical cytoreduction in the treatment of ovarian carcinosarcomaGynecologic Oncology.  133:234-237. 2014
2014 Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer centerGynecologic Oncology.  133:142-146. 2014
2013 Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancerCancer.  119:3653-3661. 2013
2013 In replyObstetrics and Gynecology.  122:906-907. 2013
2013 Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?Gynecologic Oncology.  130:317-322. 2013
2013 Growing teratoma syndrome: Brief communication and algorithm for managementAustralian and New Zealand Journal of Obstetrics and Gynaecology.  53:318-321. 2013
2013 Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trialsGynecologic Oncology.  129:251-257. 2013
2013 Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women 2013
2013 Malignant pericardial effusion and pericardial tumor involvement secondary to cervical cancer 2013
2013 Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facilityGynecologic Oncology.  131:158-162. 2013
2013 Trends in hospital volume and patterns of referral for women with gynecologic cancers: Adherence to treatment guidelines for ovarian cancer as a measure of quality careObstetrics and Gynecology.  122:905-906. 2013
2012 Re: "The utilization of palliative care in gynecologic oncology patients near the end of life".Gynecologic Oncology.  127:678-679. 2012
2012 Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervixGynecologic Oncology.  127:267-272. 2012
2012 Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapyGynecologic Oncology.  126:69-72. 2012
2012 Robotic surgery applications in the management of gynecologic malignanciesJournal of Surgical Oncology.  105:481-487. 2012
2012 Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerJournal of Clinical Oncology.  30:362-371. 2012
2012 Peripartum cardiomyopathy and acute fatty liver of pregnancy: One patient with two Zebras 2012
2011 Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot studyGynecologic Oncology.  123:360-364. 2011
2011 Erratum: Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions (Gynecologic Oncology (2010) 118 (274-277))Gynecologic Oncology.  121:643. 2011
2011 Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservationGynecologic Oncology.  121:637-638. 2011
2011 Reaction to a surgical implant foreign body masquerading as recurrent uterine sarcomaObstetrics and Gynecology.  117:450-452. 2011
2011 Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrenceGynecologic Oncology.  122:501-504. 2011
2010 Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventionsGynecologic Oncology.  118:274-277. 2010
2010 Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancyGynecologic Oncology.  117:387-388. 2010
2010 Undifferentiated uterine sarcoma presenting as a pathologic humerus fracture 2010
2009 Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: A report of 2 cases 2009
2009 Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapyInternational Journal of Gynecological Cancer.  19:888-891. 2009
2009 Cervical signet-ring cell carcinoma presenting as a synchronous primary carcinoma with uterine adenocarcinoma 2009
2008 Conservative Management of Postoperative Fever in Gynecologic Patients Undergoing Major Abdominal or Vaginal OperationsJournal of The American College of Surgeons.  207:393-397. 2008
2008 Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancerGynecologic Oncology.  110:268-269. 2008
2007 Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovaryGynecologic Oncology.  107:398-403. 2007
2007 Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: A retrospective university experienceInternational Journal of Gynecological Cancer.  17:998-1002. 2007
2007 A multi-institutional review of outcomes of endometrial stromal sarcomaGynecologic Oncology.  105:630-634. 2007
2007 Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imagingInternational Journal of Gynecological Cancer.  17:731-734. 2007
2007 A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapyGynecologic Oncology.  104:591-595. 2007
2006 Surgical staging in endometrial cancer 2006
2006 Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based ChemotherapyJournal of The American College of Surgeons.  203:527-532. 2006
2006 Inflammatory pseudotumor of pelvic lymph nodesObstetrics and Gynecology.  108:779-782. 2006
2006 Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: A university teaching hospital experienceInternational Journal of Gynecological Cancer.  16:1766-1769. 2006
2006 Synchronous primary endometrial and ovarian carcinoma in a patient with marantic endocarditisObstetrics and Gynecology.  108:748-750. 2006
2006 Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancerGynecologic Oncology.  102:338-342. 2006
2006 Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients 2006
2006 Current controversies in the biology and management of ovarian tumors of low malignant potentialWomen's Oncology Review.  6:15-25. 2006
2006 Erratum: Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter (Gene Therapy (2004) vol. 11 (645-648) 10.1038/sj.gt.3302089) 2006
2006 Use of a fascial prosthesis for management of abdominal compartment syndrome secondary to obstetric hemorrhageObstetrics and Gynecology.  107:493-496. 2006
2005 Predictors of outcomes for women with cervical carcinomaGynecologic Oncology.  99:432-436. 2005
2005 A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasiaObstetrical and Gynecological Survey.  60:96-97. 2005
2005 A prospective evaluation of "see and treat" in women with HSIL Pap smear results: Is this an appropriate strategy?Journal of Lower Genital Tract Disease.  9:2-6. 2005
2005 Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysisGynecologic Oncology.  97:387-394. 2005
2005 Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancyGynecologic Oncology.  97:713-715. 2005
2005 Validation of referral guidelines for women with pelvic massesObstetrics and Gynecology.  105:35-41. 2005
2004 Protrusio acetabuli presenting as a complex pelvic mass after total hip arthroplastyObstetrics and Gynecology.  104:1187-1189. 2004
2004 A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasiaJournal of Lower Genital Tract Disease.  8:280-284. 2004
2004 The impact of aborted radical hysterectomy in patients with cervical carcinomaGynecologic Oncology.  95:204-207. 2004
2004 Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinomaGynecologic Oncology.  94:352-362. 2004
2004 Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients.Journal of Clinical Oncology.  22:5044. 2004
2004 Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy 2004
2004 Transcriptional Blocks Limit Adenoviral Replication in Primary Ovarian TumorClinical Cancer Research.  10:3189-3194. 2004
2004 Transcriptional targeting of tumors with a novel tumor-specific survivin promoterCancer Gene Therapy.  11:256-262. 2004
2004 Immunohistochemical Evaluation of the c-kit Proto-oncogene in Sarcomas of the Uterus: A Case Series 2004
2004 Knowledge, Beliefs, and Practices Concerning Seat Belt Use during Pregnancy 2004
2004 Primary lung large cell carcinoma metastatic to the vulva: A case report and review of the literatureGynecologic Oncology.  94:829-831. 2004
2004 Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancerGynecologic Oncology.  93:429-434. 2004
2004 Single-chain antibodies: A therapeutic modality for cancer gene therapy (review).International Journal of Oncology.  24:765-771. 2004
2004 The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomyGynecologic Oncology.  92:215-219. 2004
2004 Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter 2004
2003 Primary extrarenal rhabdoid tumor of the ovary: A case report 2003
2003 Complications of indwelling venous access devices in patients with gynecologic malignanciesGynecologic Oncology.  91:591-595. 2003
2003 Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapyGynecologic Oncology.  91:470-475. 2003
2002 A guest editorial: Stump the professorObstetrical and Gynecological Survey.  57:785-787. 2002
2002 Uterine leiomyosarcoma metastatic to the thyroidObstetrics and Gynecology.  100:1122-1124. 2002
2002 Uterine leiomyosarcoma metastatic to the thyroid.Obstetrics and Gynecology.  100:1122-1124. 2002
2002 A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesisGynecologic Oncology.  87:57-63. 2002
2002 Conservative management of Stage I endometrial carcinoma after surgical stagingGynecologic Oncology.  84:194-200. 2002
1991 Team-managed care for older adults. A clinical demonstration of a community model.Journal of Gerontological Nursing.  17:25-28. 1991

Research Overview

  • Cervical cancer; ovarian cancer
  • Principal Investigator On

  • COMPLETED - Comprehensive Cancer Center Core Support Grant - Clinical Protocol and Data Management Shared Facility  awarded by National Cancer Institute/NIH/DHHS
  • Cancer Clinical Investigator Team Leadership Award  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Cancer Clinical Investigator Team Leadership Award  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Cancer Clinical Investigator Team Leadership Award (CCITLA)  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Clinical Protocol and Data Management Shared Facility  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Clinical Protocol and Data Management Shared Facility  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Clinical Protocol and Data Management Shared Facility  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS
  • Feasibility of the Institution of a Combination of Dedicated Nutritional Counseling and Exercise in Stage I Endometrial Cancer Patients following Minimally Invasive Surgery in the Post Operative Period  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY
  • Multi-Atlas and Whole Body Radiomics Approaches for Image-Guided Treatment of Gynecologic Cancers  awarded by University of California, San Diego
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • NRG Oncology Network Group Operations Center  awarded by NRG ONCOLOGY FOUNDATION
  • NRG Oncology Network Group Operations Center: Gynecologic Oncology Cancer Committee Chair  awarded by NRG ONCOLOGY FOUNDATION
  • Neoadjuvant Chemotherapy Tumor Profiling in Ovarian Cancer: Genomic and Proteomic Analysis  awarded by NRG ONCOLOGY FOUNDATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CELSION CORPORATION
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by PLEXXIKON
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MATEON THERAPEUTICS, INC.
  • Private Grant  awarded by TESARO, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by TAPIMMUNE, INC.
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by SYROS PHARMACEUTICALS INC.
  • Private Grant  awarded by GENMAB
  • Private Grant  awarded by CELSION CORPORATION
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by AGENUS, INC.
  • Private Grant  awarded by CORCEPT THERAPEUTICS, INC.
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by RUBIUS THERAPEUTICS INC
  • Private Grant  awarded by SEAGEN INC
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • SPORE in Cervical Cancer - Cervical SPORE Pilot Project (Charles Leath)  awarded by Johns Hopkins University
  • SPORE in Cervical Cancer - Pilot Project: T-cell Mediated Immunity in TC-1 Tumor Bearing Mice Treated by Sequential Radiation and Therapeutic ANAX5-E7 Protein  awarded by Johns Hopkins University
  • SPORE in Cervical Cancer - Project 4: A Phase I Safety and Immunogenicity Study of an HPV16-Specific Therapeutic Protein, TA-CIN, Administered Intraumorally during  awarded by Johns Hopkins University
  • SPORE in Cervical Cancer - Project 5  awarded by Johns Hopkins University
  • Investigator On

  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Gynecologic Oncology Group Clinical Trials  awarded by GYNECOLOGIC ONCOLOGY GROUP
  • Improving Surgical Outcomes and Experience with Patient-Centered Technology  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • OB/GYN Faculty Research Career Development Program  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • Ovarian Cancer Patient-Centered Decision Aid  awarded by University of California, Irvine
  • Overcoming PAAP Inhibitor Resistance of BACA-Deficient Ovarian Cancers  awarded by DOD - Department of Defense
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by LICOR, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by Leap Therapeutics, Inc.
  • Private Grant  awarded by DECIPHERA PHARMACEUTICALS. LLC
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by TESARO, INC.
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by VBL THERAPEUTICS
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERSANA THERAPEUTICS
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by TAKEDA PHARMACEUTICALS COMPANY LTD
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by Leap Therapeutics, Inc.
  • Private Grant  awarded by ELEVATION ONCOLOGY INC.
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by Genentech
  • Prospective Correlation of Multinational Association of Supportive Care of Cancer Risk-Index Score with Management of Gynecologic Oncology Patients with Neutropenic Fever  awarded by University of Oklahoma
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University
  • SPORE in Cervical Cancer - Project 2  awarded by Johns Hopkins University
  • SPORE in Cervical Cancer - Project 2: DNA Prime-protein Boost Vaccination to treat HPV16 Infection in Women with ASC-US or LSIL  awarded by Johns Hopkins University
  • UAB 1753 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer  awarded by University of Chicago ^
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB 1788: Pilot Study of Daily Exemestane in Women with Complex Alypical Hyperplasia of The Endometrium / Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer (Fixed Price)  awarded by University of Wisconsin-Madison
  • UAB 1788; Pilot Study of Daily Exemestane in Women with Complex Alypical Hyperplasia of The Endometrium / Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer (Cost Reimbursable)  awarded by University of Wisconsin-Madison
  • UAB 18107 - A Phase 2, Single Arm Study of Atezolizumab + Bevacizumab in Women with Advanced, Recurrent or Persistent Endometrial Cancer  awarded by University of Oklahoma
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY
  • Teaching Activities

  • STP2083 - INTENSIVE GYNECOLOGIC ONCOLOGY (Spring Term 2021) 2021
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2020) 2020
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2020) 2020
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2020) 2020
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2019) 2019
  • STP10455 - ADVANCED GYNECOLOGIC ONCOLOGY (Spring Term 2019) 2019
  • STP2083 - INTENSIVE GYNECOLOGIC ONCOLOGY (Spring Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2019) 2019
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2018) 2018
  • STP2083 - INTENSIVE GYNECOLOGIC ONCOLOGY (Fall Term 2018) 2018
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2018) 2018
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2018) 2018
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2018) 2018
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2018) 2018
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2018) 2018
  • STP2083 - INTENSIVE GYNECOLOGIC ONCOLOGY (Spring Term 2018) 2018
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2018) 2018
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2018) 2018
  • STP2083 - INTENSIVE GYNECOLOGIC ONCOLOGY (Fall Term 2017) 2017
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2017) 2017
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2016) 2016
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2016) 2016
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2016) 2016
  • 40-405 - GYNECOLOGIC ONCOLOGY (Fall Term 2016) 2016
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2016) 2016
  • 40-405 - GYNECOLOGIC ONCOLOGY (Spring Term 2016) 2016
  • Education And Training

  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Medical University of South Carolina 1998
  • Full Name

  • Charles Leath